|
| 38095056 | HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced <i>EGFR</i>-mutated NSCLC after a third-generation EGFR TKI. | Future Oncol | 2024 |
| 37806383 | Real-World Genomic Profile of EGFR Second-Site Mutations and Other Osimertinib Resistance Mechanisms and Clinical Landscape of NSCLC Post-Osimertinib. | J Thorac Oncol | 2024 |
| 38042525 | CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor-Mutated Advanced Non-Small-Cell Lung Cancer. | J Clin Oncol | 2024 |
| 34524205 | Prediction Model for Tumor Volume Nadir in EGFR -mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors. | J Thorac Imaging | 2023 |
| 37552839 | MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer. | Cancer Discov | 2023 |
| 37694347 | Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non-Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial. | J Clin Oncol | 2023 |
| 37579253 | Germline <i>EGFR</i> Mutations and Familial Lung Cancer. | J Clin Oncol | 2023 |
| 37689979 | HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. | J Clin Oncol | 2023 |
| 37937763 | Osimertinib with or without Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLC. | N Engl J Med | 2023 |
| 37541244 | Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer. | Cancer Cell | 2023 |
| 37732171 | Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study. | JTO Clin Res Rep | 2023 |
| 37599043 | Chasing EGFR Mutations in the Plasma of Patients With Resected NSCLC: Lessons in the ADAURA Era. | J Thorac Oncol | 2023 |
| 37024582 | Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. | Nat Genet | 2023 |
| 37121400 | Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma. | Ann Oncol | 2023 |
| 37384867 | Exceptional Response to Bromodomain and Extraterminal Domain Inhibitor Therapy With BMS-986158 in <i>BRD4-NUTM1</i> NUT Carcinoma Harboring a <i>BRD4</i> Splice Site Mutation. | JCO Precis Oncol | 2023 |
| 37384411 | Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer. | J Clin Invest | 2023 |
| 37212796 | HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic <i>EGFR</i>-mutated NSCLC. | Future Oncol | 2023 |
| 37279096 | Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients. | Clin Cancer Res | 2023 |
| 37097610 | Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer. | Clin Cancer Res | 2023 |
| 37327468 | Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With <i>KRAS<sup>G12C</sup></i>-Mutated Non-Small-Cell Lung Cancer Who Have Untreated CNS Metastases. | J Clin Oncol | 2023 |
| 37224424 | Antibody-Drug Conjugates in Lung Cancer: Recent Advances and Implementing Strategies. | J Clin Oncol | 2023 |
| 36537204 | Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for <i>EGFR</i> exon 20 insertion-positive non-small cell lung cancer. | Expert Rev Anticancer Ther | 2023 |
| 36264123 | Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. | Cancer Discov | 2023 |
| 34534430 | Trastuzumab Deruxtecan in <i>HER2</i>-Mutant Non-Small-Cell Lung Cancer. | N Engl J Med | 2022 |
| 35708671 | Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. | JAMA Oncol | 2022 |
| 35678717 | Activation of Tumor-Cell STING Primes NK-Cell Therapy. | Cancer Immunol Res | 2022 |
| 35613620 | ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1. | Mol Cell | 2022 |
| 35507495 | Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. | N Engl J Med | 2022 |
| 35507496 | Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. Reply. | N Engl J Med | 2022 |
| 35507494 | Trastuzumab Deruxtecan in Non-Small-Cell Lung Cancer. | N Engl J Med | 2022 |
| 35735998 | Osimertinib plus Selumetinib in EGFR-Mutated Non-Small Cell Lung Cancer After Progression on EGFR-TKIs: A Phase Ib, Open-Label, Multicenter Trial (TATTON Part B). | Clin Cancer Res | 2022 |
| 35404393 | Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations. | Cancer Discov | 2022 |
| 35378251 | Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. | Bioorg Med Chem Lett | 2022 |
| 35534503 | Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. | Nat Commun | 2022 |
| 35365776 | Kinase drug discovery 20 years after imatinib. | Nat Rev Drug Discov | 2022 |
| 35422503 | An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. | Nat Cancer | 2022 |
| 35658005 | Adagrasib in Non-Small-Cell Lung Cancer Harboring a <i>KRAS<sup>G12C</sup></i> Mutation. | N Engl J Med | 2022 |
| 36614913 | Mobocertinib (TAK-788) in <i>EGFR</i> Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort. | J Clin Med | 2022 |
| 36455195 | Response to MEK Inhibitor Therapy in <i>MAP2K1</i> (<i>MEK1</i>) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of <i>MAP2K1</i> Mutations in Non-Small-Cell Lung Cancer. | JCO Precis Oncol | 2022 |
| 36150391 | MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer. | Cancer Cell | 2022 |
| 35872166 | Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS<sup>G12D</sup>-mutated non-small-cell lung cancer. | Ann Oncol | 2022 |
| 36066413 | MET-Induced CD73 Restrains STING-Mediated Immunogenicity of EGFR-Mutant Lung Cancer. | Cancer Res | 2022 |
| 36170509 | Adagrasib in Non-Small-Cell Lung Cancer. Reply. | N Engl J Med | 2022 |
| 36170508 | Adagrasib in Non-Small-Cell Lung Cancer. | N Engl J Med | 2022 |
| 36384036 | Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19. | J Med Chem | 2022 |
| 36153311 | Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors. | Nat Commun | 2022 |
| 36152477 | Safety of image guided research biopsies in patients with thoracic malignancies. | Lung Cancer | 2022 |
| 35181499 | Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial. | J Thorac Oncol | 2022 |
| 35149586 | A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer. | Cancer Res | 2022 |
| 35091439 | Comparative Analysis and Isoform-Specific Therapeutic Vulnerabilities of KRAS Mutations in Non-Small Cell Lung Cancer. | Clin Cancer Res | 2022 |